The drug Cytokinetics is placing its hopes on is aficamten, a selective small-molecule inhibitor of cardiac myosin. The drug ...

For newborns with HCM, the preferred first-line treatment is Propranolol, a class of medication known as a beta-blocker (a type of medication that slows down the heart). If hypertrophic cardiomyopathy ...

Patients who have hypertrophic cardiomyopathy experience enlargement and thickening of their heart muscle. While there are no current treatment options available to reverse hypertrophic cardiomyopathy ...

RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on November 13 and set a price ...

Opens in a new tab or window A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH ...

Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...

Background: Mavacamten, a cardiac myosin inhibitor, is approved across 5 continents for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Long-term data of mavacamten are available from ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Researchers from Affinia Therapeutics Inc. have described the development and preclinical evaluation of a new AAV-based gene therapy, designed using a novel cardiotropic capsid, for the potential ...